PD-Rx Pharmaceuticals, Inc. (PDRX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $5.32M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPD-Rx Pharmaceuticals, Inc. (PDRX) trades at $3.10. PD-Rx Pharmaceuticals, Inc. specializes in pre-packaging and distributing approximately 2,600 ready-to-dispense medications across the U.S. healthcare sector. Market cap: $5.32M, Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for PDRX: PDRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
PD-Rx Pharmaceuticals, Inc. (PDRX) Healthcare & Pipeline Overview
PD-Rx Pharmaceuticals, Inc. is a U.S.-based medical distributor specializing in the pre-packaging and distribution of over 2,600 ready-to-dispense medications. It provides an online prescription management platform and pharmaceutical sampling programs, serving physicians, retail pharmacies, and medical clinics to streamline point-of-care dispensing and reduce MCO costs.
What Is the Investment Thesis for PDRX?
PD-Rx Pharmaceuticals, Inc. operates within the essential medical distribution sector, providing pre-packaged pharmaceuticals and integrated dispensing solutions to U.S. healthcare providers. Despite a current market capitalization of $5.32M and a negative profit margin of -1.4%, the company's value proposition lies in its specialized niche of pre-packaged medications and its PD-Rx Net platform, which addresses efficiency needs at the point of care. Growth catalysts include the ongoing demand for streamlined medication dispensing, the potential expansion of its pharmaceutical sampling program to further reduce MCO costs, and the continuous enhancement of its 2,600-product catalog. However, the company's listing on the OTC Other tier introduces significant risks, including limited liquidity, unknown disclosure status, and inherent market volatility. Investors should closely monitor the company's ability to achieve sustained profitability, improve financial transparency, and navigate the competitive and regulatory landscape of pharmaceutical distribution.
Based on FMP financials and quantitative analysis
PDRX Key Highlights
Market capitalization stands at $5.32M, reflecting its status as a micro-cap entity within the healthcare sector.
- The company reported a profit margin of -1.4%, indicating current unprofitability in its operations.
- PD-Rx Pharmaceuticals, Inc. maintains an extensive catalog of approximately 2,600 ready-to-dispense pharmaceutical products.
- The company employs 28 individuals, suggesting a lean operational structure for its specialized distribution services.
- Founded in 1986, PD-Rx Pharmaceuticals, Inc. has over three decades of operational history in the U.S. pharmaceutical distribution market.
Who Are PDRX's Competitors?
PDRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ACH Accendra Health, Inc. | $0.45 | -10.73% | $35.0M | — |
| RDGT Ridgetech Inc. | $0.89 | +1.44% | 33 5-pillar | |
| PBH Prestige Consumer Healthcare Inc. | $45.60 | +0.75% | $2.16B | 62 5-pillar |
| GRDN Guardian Pharmacy Services, Inc. | $42.10 | -0.66% | $2.70B | 97 5-pillar |
| HSIC Henry Schein, Inc. | $84.23 | -0.77% | $9.67B | 75 5-pillar |
| CAH Cardinal Health, Inc. | $233.12 | +2.11% | $54.6B | 88 5-pillar |
| COR Cencora, Inc. | $314.93 | +1.90% | $61.3B | 81 5-pillar |
| MCK McKesson Corporation | $915.45 | +1.46% | $107B | 90 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PDRX's Key Strengths?
Specialized focus on pre-packaged, ready-to-dispense medications addresses a specific market need for efficiency.
- Extensive catalog of approximately 2,600 pharmaceutical products provides broad coverage.
- Proprietary PD-Rx Net online platform streamlines prescription management at the point of care.
- Pharmaceutical sampling program offers a unique value proposition for MCOs to reduce costs and improve patient access.
What Are PDRX's Weaknesses?
Negative profit margin of -1.4% indicates operational unprofitability.
- Market capitalization of $5.32M and 28 employees suggest a small operational scale.
- OTC Other tier listing results in limited liquidity, high volatility, and unknown disclosure status.
- Beta of -1366978.48 indicates extreme and unusual price sensitivity, potentially due to low trading volume.
What Could Drive PDRX Stock Higher?
PDRX catalyst: Continued adoption and expansion of the PD-Rx Net online platform by healthcare providers, driving efficiency and potential recurring revenue streams.
- Increased participation and success of the pharmaceutical sampling program in reducing costs for Managed Care Organizations, leading to expanded partnerships.
- Potential for the introduction of new pharmaceutical products or expansion of the existing 2,600-item catalog to address evolving market demands and therapeutic areas.
- Any future improvements in financial disclosure or transparency, which could potentially attract broader investor interest and improve market perception.
What Are the Key Risks for PDRX?
Negative return on equity (-2.5%) — the business is not currently generating profit on shareholder capital.
- The company's current negative profit margin of -1.4% indicates ongoing operational unprofitability, posing a risk to sustained financial health.
- Significant liquidity constraints and high price volatility due to its listing on the OTC Other tier, making it challenging for investors to trade shares efficiently.
- Regulatory changes within the U.S. pharmaceutical distribution industry could impact operational costs, compliance requirements, and market access.
- Intense competition from larger, more financially robust pharmaceutical distributors could limit market share growth and pricing power.
- The 'Unknown' disclosure status limits investor access to critical financial and operational information, increasing investment uncertainty and risk.
What Are the Growth Opportunities for PDRX?
- **Expansion of PD-Rx Net Adoption:** The increasing digitalization of healthcare and the demand for efficient prescription management systems present a significant growth opportunity. PD-Rx Net, by streamlining point-of-care tracking and label generation, addresses a critical need for healthcare providers. Expanding the user base of this platform through targeted marketing to clinics and physician groups could capture a larger share of the digital health market, which is projected to grow substantially as providers seek to reduce administrative burdens and improve patient care workflows. This digital solution offers scalability beyond physical product distribution.
- **Growth in Pharmaceutical Sampling Programs:** Managed Care Organizations (MCOs) are under continuous pressure to reduce medication costs while ensuring patient access. PD-Rx Pharmaceuticals' sampling program directly addresses this by offering cost-saving solutions to MCOs and enabling physicians to provide complimentary, pre-filled prescriptions. Expanding the reach and scope of this program, potentially by partnering with more MCOs or increasing the variety of sampled medications, could tap into a growing market for cost-effective patient care solutions, enhancing both revenue streams and market penetration.
- **Increased Demand for Pre-packaged Medications:** The healthcare industry continually seeks efficiencies, and pre-packaged medications offer significant advantages in terms of reduced dispensing errors, improved inventory management, and time savings for healthcare professionals. As clinics and pharmacies face staffing challenges and increased patient volumes, the demand for ready-to-dispense products is likely to grow. PD-Rx Pharmaceuticals, with its extensive catalog of 2,600 such medications, is well-positioned to capitalize on this trend by expanding its distribution network and increasing market penetration among its target customer segments.
- **Diversification and Expansion of Product Catalog:** While PD-Rx Pharmaceuticals already offers approximately 2,600 medications, there is ongoing opportunity to strategically diversify and expand this catalog. This could involve introducing new therapeutic categories, incorporating more specialized or high-demand medications, or even exploring generic alternatives to popular branded drugs. By continuously updating and broadening its product offerings, the company can cater to evolving medical needs, attract new customers, and increase its market share within the competitive pharmaceutical distribution landscape, potentially capturing additional revenue streams.
- **Enhanced Market Penetration within the U.S.:** The company currently serves the 'United States healthcare sector,' implying a broad but potentially uneven market presence. There is a significant opportunity to deepen market penetration in underserved or high-growth regions within the U.S. By identifying areas with high concentrations of individual physicians, medical clinics, or retail pharmacies that could benefit from their specialized pre-packaging and dispensing solutions, PD-Rx Pharmaceuticals can strategically expand its sales force and distribution logistics. This targeted geographic expansion could lead to increased customer acquisition and higher sales volumes across the country.
What Threats Does PDRX Face?
- Intense competition from larger, more established pharmaceutical distributors with greater resources.
- Potential for adverse changes in pharmaceutical regulations impacting distribution and dispensing practices.
- Economic downturns or changes in healthcare spending policies could reduce demand for services.
- Inherent risks and limited investor confidence associated with OTC Other tier stocks, including difficulty in raising capital.
What Are PDRX's Competitive Advantages?
- **Specialized Niche:** Focus on pre-packaging and distributing ready-to-dispense medications, catering to specific needs for point-of-care dispensing.
- **Extensive Product Catalog:** An established offering of approximately 2,600 medications provides a broad selection for diverse medical requirements.
- **Integrated Digital Platform:** PD-Rx Net offers a proprietary online solution for prescription tracking and label generation, enhancing customer stickiness.
- **MCO Cost Reduction Programs:** The pharmaceutical sampling program provides a unique value proposition for Managed Care Organizations, fostering strategic partnerships.
- **Professional Support:** Access to a team of pharmacists and physicians provides expert consultation and strengthens client relationships.
What Does PDRX Do?
PD-Rx Pharmaceuticals, Inc., established in 1986 and headquartered in Oklahoma City, Oklahoma, operates as a specialized entity within the United States healthcare sector, focusing on the pre-packaging and distribution of pharmaceutical products. The company has cultivated an extensive catalog, offering approximately 2,600 ready-to-dispense medications. This comprehensive range includes various formulations such as topical treatments, creams, ointments, specialized ophthalmics, otics, oral liquids, and suspensions, catering to a broad spectrum of medical needs. Beyond its core product offerings, PD-Rx Pharmaceuticals, Inc. distinguishes itself by integrating technological solutions and supportive services designed to enhance efficiency for healthcare providers. A cornerstone of its service portfolio is PD-Rx Net, an innovative online platform that significantly streamlines prescription management. This platform empowers healthcare professionals to meticulously track medications dispensed directly at the point of care, while also facilitating the generation of necessary labels for on-site prescription filling. Complementing its digital solutions, the company also provides a practical manual dispensing system, which comprises 10 record-keeping labels paired with 10 bottle trays, specifically engineered for convenient use by physicians engaged in direct prescription dispensing. Furthermore, PD-Rx Pharmaceuticals, Inc. extends professional assistance through a dedicated team of pharmacists and physicians, ensuring expert support for its clientele. A particularly notable service is its pharmaceutical sampling program, strategically designed to assist Managed Care Organizations (MCOs) in achieving medication cost reductions. Simultaneously, this program enables medical professionals to offer complimentary, pre-filled prescriptions to their patients, improving access and adherence. The company's diverse customer base encompasses individual physicians, retail pharmacies, and medical clinics, underscoring its integral role in the pharmaceutical supply chain.
What Products and Services Does PDRX Offer?
- Pre-package a wide range of pharmaceutical products for the U.S. healthcare sector.
- Distribute approximately 2,600 ready-to-dispense medications, including topicals, ophthalmics, otics, oral liquids, and suspensions.
- Provide PD-Rx Net, an online platform for tracking dispensed medications and generating prescription labels at the point of care.
- Offer a manual dispensing system with record-keeping labels and bottle trays for physicians.
- Support clients with professional assistance from a team of pharmacists and physicians.
- Operate a pharmaceutical sampling program to help Managed Care Organizations reduce medication costs.
- Enable medical professionals to offer complimentary, pre-filled prescriptions to patients through their sampling program.
- Cater to a diverse customer base including individual physicians, retail pharmacies, and medical clinics.
How Does PDRX Make Money?
- Generates revenue primarily through the sale and distribution of its extensive catalog of pre-packaged pharmaceutical products.
- Offers value-added services like the PD-Rx Net online platform and manual dispensing systems, potentially generating service fees or enhancing product sales.
- Facilitates pharmaceutical sampling programs, which likely involve agreements with Managed Care Organizations (MCOs) for cost reduction initiatives.
- Serves a B2B customer base, including physicians, retail pharmacies, and medical clinics, acting as a key intermediary in the pharmaceutical supply chain.
What Industry Does PDRX Operate In?
PD-Rx Pharmaceuticals, Inc. operates within the highly regulated and essential Medical - Distribution industry, a critical component of the broader Healthcare sector. This industry is characterized by the efficient movement of pharmaceutical products from manufacturers to various healthcare providers and patients. Key market trends include increasing demand for supply chain efficiency, cost containment pressures from Managed Care Organizations (MCOs), and a growing emphasis on point-of-care dispensing solutions. The competitive landscape often features large, integrated distributors alongside specialized niche players. PD-Rx Pharmaceuticals, Inc. carves out its position by focusing specifically on pre-packaging and distributing ready-to-dispense medications, complemented by its PD-Rx Net online platform. This specialization allows it to cater to specific needs of individual physicians, retail pharmacies, and medical clinics, differentiating it from broader-line distributors by offering tailored solutions for on-site dispensing and MCO cost reduction.
Who Are PDRX's Key Customers?
- Individual physicians who dispense prescriptions directly to patients.
- Retail pharmacies seeking pre-packaged medications for efficiency.
- Medical clinics requiring streamlined medication management and dispensing solutions.
- Managed Care Organizations (MCOs) benefiting from pharmaceutical sampling programs for cost reduction.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Company Profile
PD-Rx Pharmaceuticals, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Oklahoma City, US. The company is led by CEO Robert D. Holsey. PDRX has traded publicly since 2000.
How PD-Rx Pharmaceuticals, Inc. Is Valued
PD-Rx Pharmaceuticals, Inc. carries a market capitalization of $5.32M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for PD-Rx Pharmaceuticals, Inc. stands at -2.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.1%, showing how much profit it generates from its asset base. Its free cash flow yield is 14.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.4%, the inverse of the P/E and a quick read on earnings relative to price.
PDRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Specialized focus on pre-packaged, ready-to-dispense medications addresses a specific market need for efficiency.
- Extensive catalog of approximately 2,600 pharmaceutical products provides broad coverage.
- Proprietary PD-Rx Net online platform streamlines prescription management at the point of care.
- Pharmaceutical sampling program offers a unique value proposition for MCOs to reduce costs and improve patient access.
Bear Case
- Negative profit margin of -1.4% indicates operational unprofitability.
- Market capitalization of $5.32M and 28 employees suggest a small operational scale.
- OTC Other tier listing results in limited liquidity, high volatility, and unknown disclosure status.
- Beta of -1366978.48 indicates extreme and unusual price sensitivity, potentially due to low trading volume.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
PDRX Latest News
No recent news available for PDRX.
PDRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PDRX.
Price Targets
Wall Street price target analysis for PDRX.
PDRX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PDRX; grades run from A+ (80-100) to F (below 30).
Leadership: Robert D. Holsey
CEO
Robert D. Holsey serves as the CEO of PD-Rx Pharmaceuticals, Inc., overseeing the company's strategic direction and operational management. His leadership is central to guiding the company's mission in pre-packaging and distributing pharmaceutical products across the U.S. healthcare sector. With a focus on managing the company's 28 employees, Mr. Holsey's role encompasses ensuring the efficiency of the distribution network, the development of solutions like PD-Rx Net, and the expansion of key programs such as pharmaceutical sampling for Managed Care Organizations. His tenure involves navigating the complexities of the medical distribution industry and maintaining relationships with a diverse customer base.
Track Record: Under Robert D. Holsey's leadership, PD-Rx Pharmaceuticals, Inc. has maintained its specialized position in the pre-packaged pharmaceutical market since its founding in 1986. His management has overseen the development and implementation of the PD-Rx Net online platform, enhancing prescription management capabilities for healthcare providers. He has also guided the company's pharmaceutical sampling program, a key initiative for MCO cost reduction. His focus has been on sustaining the company's extensive product catalog and supporting its customer base of physicians, pharmacies, and clinics.
PDRX OTC Market Information
PD-Rx Pharmaceuticals, Inc. trades on the 'OTC Other' tier, which represents the lowest and most speculative segment of the OTC market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and disclosure, OTC Other companies have minimal or no public disclosure requirements. This tier typically includes shell companies, defunct entities, or those with limited operations, making it significantly different from the more transparent and regulated OTCQX or OTCQB tiers. The lack of robust financial reporting and oversight on this tier contributes to higher investment risk.
- OTC Tier: OTC Other
- **Extreme Volatility:** OTC Other stocks are highly susceptible to extreme price fluctuations due to low trading volumes and speculative interest.
- **Limited Information:** The 'Unknown' disclosure status means investors have minimal or no access to financial statements or operational updates, hindering informed decision-making.
- **Illiquidity:** Low trading volume can make it difficult to buy or sell shares, potentially leading to significant losses if an investor needs to exit a position quickly.
- **Fraud Risk:** The lack of regulatory oversight and transparency in the OTC Other tier can expose investors to a higher risk of fraudulent activities or pump-and-dump schemes.
- **Valuation Challenges:** Without reliable financial data and active market participation, accurately valuing the company's stock becomes exceptionally challenging and speculative.
- Verify any available financial statements or disclosures directly from the company or regulatory bodies, if they exist.
- Thoroughly research the company's business model, products, and services to understand its operational legitimacy.
- Investigate the background and track record of the management team beyond what is publicly stated.
- Assess the actual market demand for their specific pre-packaged pharmaceutical products and digital solutions.
- Attempt to find any news, press releases, or third-party reports that might offer insights into company activities.
- Understand the regulatory environment for pharmaceutical distribution and any compliance requirements PD-Rx Pharmaceuticals must meet.
- Evaluate the company's customer base and any long-term contracts or partnerships that could indicate stability.
- **Established Operations:** Founded in 1986, the company has a long operational history in the healthcare sector.
- **Specific Product & Service Offerings:** It provides a clear and tangible service (pre-packaging, distribution of 2,600 medications) and a distinct product (PD-Rx Net platform).
- **Physical Headquarters:** The company maintains a headquarters in Oklahoma City, Oklahoma, indicating a physical presence.
- **Identified Leadership:** The CEO, Robert D. Holsey, is named, providing a point of contact for leadership accountability.
- **Defined Customer Base:** It serves identifiable customer segments including physicians, retail pharmacies, and medical clinics.
PDRX Healthcare Stock FAQ
Is PDRX a good stock to buy?
Stock Expert AI does not rate PDRX buy, sell or hold. PD-Rx Pharmaceuticals, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PDRX stock price today?
The last price recorded on this page for PD-Rx Pharmaceuticals, Inc. (PDRX) is $3.10, as of the Oct 5, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does PD-Rx Pharmaceuticals, Inc. differentiate itself in the medical distribution market?
PD-Rx Pharmaceuticals, Inc. differentiates itself through a specialized focus on pre-packaged, ready-to-dispense medications, directly addressing the efficiency needs of healthcare providers at the point of care.
What are the key factors to evaluate for PDRX?
Evaluate PDRX on fundamentals, analyst consensus, and risk factors. Founded in 1986, PD-Rx Pharmaceuticals, Inc. has over three decades of operational history in the U.S. pharmaceutical distribution market. Not financial advice.
How frequently does PDRX data refresh on this page?
PDRX's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PDRX's recent stock price performance?
PD-Rx Pharmaceuticals, Inc. (PDRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on pre-packaged, ready-to-dispense medications addresses a specific market need for efficiency. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PDRX overvalued or undervalued right now?
PD-Rx Pharmaceuticals, Inc. (PDRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PDRX before investing?
Before investing in PD-Rx Pharmaceuticals, Inc. (PDRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based solely on the provided source data. No external research was conducted.
- The 'tenureYears' for the CEO is null due to insufficient date information in the source.
- The 'AI Insight' was used as a source for SWOT and risk analysis where applicable, adhering to the rule of using provided source data.